CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 195 enrolled
Drug / intervention
lepirudin +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01304238
NCT01304238N/ACompleted
CompareCT.gov

Systematische Dokumentation Von Patienten Mit Akutem HIT-Verdacht

GlaxoSmithKline·observational·Posted Feb 25, 2011·Updated Jul 6, 2017

In Brief

An observational study evaluating lepirudin, danaparoid, and 2 other interventions for Acute HIT II (Heparin-induced Thrombocytopenia Type II). Completed, enrolled 195 participants.

Detailed Summary

The purpose of this retrospective registry is to collect data about patients with acute HIT II (Heparin-induced Thrombocytopenia type II) which were treated with Lepirudin, Danaparoid, Argatroban or Fondaparinux. It is a main objective of this registry to mirror the daily routine in this indication in Germany.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsAcute HIT II (Heparin-induced Thrombocytopenia Type II)
Countries--
Collaborators--

Timeline

N/ACompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedFeb 25, 2011
Enrollment StartFeb 1, 2009
Primary CompletionJan 1, 2010
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 15.4 years ago

Interventions

lepirudindrug

lepirudin

danaparoiddrug

danaparoid

argatrobandrug

argatroban

fondaparinuxdrug

fondaparinux